The Italy In-Vitro Diagnostics Market was valued at US$ 2.61 Billion in 2023, and will grow to US$ 4.67 Billion by 2032, with a CAGR of 6.68% from 2024 to 2032. Growth is also anticipated to be fueled by the nation's growing chronic disease prevalence and the significant investments made in R&D by industry leaders to create cutting-edge technologies for investigating novel approaches to disease detection. Italy is predicted to see a rise in the prevalence of a number of diseases, including cancer, autoimmune disorders, myocardial infarctions, arrhythmias, and inflammatory ailments, which will drive up demand for IVD testing.Italy in-vitro Diagnostics Market was US$ 2.44 Billion in 2022
Italy In-Vitro Diagnostics Market Overview
The term 'in-vitro diagnostics' (IVD) describes a broad range of medical procedures used to diagnose illnesses, track the effectiveness of treatment, and evaluate general health status using samples of human fluids, tissues, or cells that are kept outside of the body. Numerous methods and tools, such as immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology, are used to conduct these tests in laboratory settings. These tests make it possible to identify illnesses early, which enables prompt intervention and the start of therapy. IVD testing provide personalized medicine by facilitating quick and precise results that inform customized treatment plans based on unique patient features. Additionally, by offering insightful knowledge about biological systems, in-vitro trials help researchers and scientists advance areas like pharmacology, biotechnology, and medicine. They are vital resources for comprehending basic biological processes and creating novel approaches to health problems.The increasing occurrence of chronic illnesses is a major driver propelling the market's expansion. The need for early diagnosis utilizing IVD devices is rising due to the number of patients with various infectious and chronic diseases. As a result, more people are using in-vitro diagnostics for a variety of ailments. For example, a December 2022 report published by Nova Agency indicated that 390,700 new cases of cancer were expected in Italy year 2022. In a similar vein, the International Diabetes Federation (IDF) estimates that 4.47 million Italians suffered from diabetes in 2021 and that number is expected to rise to 4.59 million by 2045. As a result, the high prevalence of disease among Italians is fueling the nation's adoption of in-vitro diagnostic instruments and raising the demand for early disease diagnosis.
Growth Factors in the Italy In-Vitro Diagnostics Industry
Growth in the In-Vitro Diagnostics Market is Driven by Increasing Healthcare Spending in Italy
The in-vitro diagnostics business in Italy is expanding thanks in large part to the notable rise in healthcare spending. Italy has made large investments in healthcare, amounting to USD 4291 per capita and accounting for 9.0% of its GDP, as per an OECD assessment. This indicates a strong commitment to improving healthcare infrastructure and services. This large donation encourages advancements in patient care delivery by enabling healthcare providers to use cutting-edge diagnostic tools and creative solutions.Information and Communications Technology (ICT) Integration in Healthcare Fuels Market Expansion
The growing in-vitro diagnostics business in Italy is mostly being driven by the integration of Information and Communications Technology (ICT) in healthcare. With a 7% rise from 2021 to 2022, Italy spent USD 1.98 billion on ICT for healthcare. Healthcare diagnostic processes can be made more accurate and efficient by leveraging digital tools like data analytics, telemedicine platforms, and electronic health records. ICT facilitates easy communication between labs, medical professionals, and patients, allowing for the early diagnosis of illnesses and the modification of treatment plans as necessary. ICT developments also make it possible to remotely monitor patients' health problems, which allows for quick intervention and the application of preventive healthcare measures.Italy In-Vitro Diagnostics Market Company Overview
Some of the industry leaders seen in the Italy In-Vitro Diagnostics Market Includes Roche Diagnostics, Abbott Diagnostics, Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific, Sysmex Corporation.Italy In-Vitro Diagnostics Market News
- In April 2023, in order to commercialize the DiviTum TKa test in Italy, Biovica International and IT Health Fusion entered into a business cooperation. Thymidine kinase activity (TKa) in human serum is measured semi-quantitatively using this in-vitro diagnostic instrument.
- In May 2022, Italy implemented the new EU In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR) on May 26, 2022. While some legacy devices will benefit from transitional periods, the IVDR criteria now apply to all new IVDs as well as those low-risk IVDs that are already marketed.
Test Types - Market breakup in 11 viewpoints:
- ELISA & CLIA
- PCR
- Rapid Test
- Fluorescence Immunoassays (FIA)
- In Situ Hybridization
- Transcription Mediated Amplification
- Sequencing
- Colorimetric Immunoassay
- Radioimmunoassay (RIA)
- Isothermal Nucleic Acid Amplification Technology
- Others
Products - Market breakup in 3 viewpoints:
- Services
- Instruments
- Reagents
Technology - Market breakup in 7 viewpoints:
- Immunoassay
- Clinical Chemistry
- Molecular Diagnostics/Genetics
- Hematology
- Microbiology
- Coagulation
- Others
Application - Market breakup in 8 viewpoints:
- Infectious Disease
- Diabetes
- Cardiology
- Oncology
- Nephrology
- Autoimmune Diseases
- Drug Testing
- Other Applications
End User - Market breakup in 4 viewpoints:
- Hospitals
- Laboratories
- Home - Care
- Others
The key players have been covered from 5 viewpoints:
- Overviews
- Key Person
- Recent Developments & Strategies
- Product Portfolio & Product Launch in Last 1 Year
- Revenue
Company Analysis:
- Roche Diagnostics
- Abbott Diagnostics
- Siemens Healthineers
- Danaher Corporation
- Thermo Fisher Scientific
- Sysmex Corporation
Table of Contents
Companies Mentioned
- Roche Diagnostics
- Abbott Diagnostics
- Siemens Healthineers
- Danaher Corporation
- Thermo Fisher Scientific
- Sysmex Corporation
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 180 |
| Published | August 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 2.61 Billion |
| Forecasted Market Value ( USD | $ 4.67 Billion |
| Compound Annual Growth Rate | 6.6% |
| Regions Covered | Italy |
| No. of Companies Mentioned | 6 |
